Hypersensitivity to Aspirin and Other Non-steroidal Anti-inflammatory Drugs

  • Adile Berna Dursun
  • Engin Dursun
  • D. Donald Stevenson


Non-steroidal anti-inflammatory drug (NSAIDs) are documented as causing the second highest number of medication-related hypersenstivity reactions and as the third highest reason for allergy consulations. The prevalence of hypersentivity to NSAIDs in the general population at large between 0.5 and 2.5%. Estimation of prevalence depends, however, on diagnostic methodology and patient characteristics, such as gender, age and the presence of comorbidity such as asthma, persistent rhinosinusitis, nasal polyps and chronic hives. Being asthmatics carries a 10-20% risk, whilst being asthmatic and having nasal polyposis carries a 30-40% risk of having NSAID-hypersensitivity. Children are less frequently affected than adults; and there is a female predilection. Classification of NSAID-hypersensitivity are based on clinical picture, whether an underlying pathology is present, and extent to which cross-reaction occurs with other members of the COX-1 inhibitor group. NSAID-exacerbated respiratory disease (NERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of NSAID. Disscussion in this chapter is confined to NERD.


Aspirin Non-steroidal anti-inflammatory drugs (NSAIDs) Hypersensitivity Medication-related hypersensitivity response Cyclooxygenase COX-1 COX-2 


  1. 1.
    Szczeklik A, Nizankowska E, Sanak M. Hypersensitivity to aspirin and other NSIADs: mechanisms, clinical presentation and management. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007. p. 340–9.Google Scholar
  2. 2.
    Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004;24(3):491–505, vii.PubMedGoogle Scholar
  3. 3.
    Kowalski M, Stevenson D. Classification of reactions to nonsteroidal antiinflammatory drugs. Immunol Allergy Clin North Am. 2013;33:135–45.PubMedGoogle Scholar
  4. 4.
    Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–32.PubMedGoogle Scholar
  5. 5.
    Park HS, Kowalski M, Sanchez-Borges M. Hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs. In: Adkinson NF, Bochner BS, Burks W, et al., editors. Middleton’s allergy principles & practice. Philadelphia: Mosby Elsevier; 2014. p. 1296–309.Google Scholar
  6. 6.
    Yilmaz O, Ertoy Karagol IH, Bakirtas A, Topal E, Celik GE, Demirsoy MS, et al. Challenge-proven nonsteroidal anti-inflammatory drug hypersensitivity in children. Allergy. 2013;68(12):1555–61.PubMedGoogle Scholar
  7. 7.
    Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011;3(1):3–10.PubMedGoogle Scholar
  8. 8.
    Bavbek S, Dursun B, Dursun E, Korkmaz H, Sertkaya Karasoy D. The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors. Am J Rhinol Allergy. 2011;25(6):411–5.PubMedGoogle Scholar
  9. 9.
    Bavbek S, Yilmaz I, Celik G, Aydin O, Erkekol FO, Orman A, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergol Immunopathol (Madr). 2012;40(4):225–30.Google Scholar
  10. 10.
    Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87(3):177–80.PubMedGoogle Scholar
  11. 11.
    Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420–5.PubMedGoogle Scholar
  12. 12.
    White AA, Bosso JV, Stevenson DD. The clinical dilemma of “silent desensitization” in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2013;34(4):378–82.PubMedGoogle Scholar
  13. 13.
    Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508.PubMedGoogle Scholar
  14. 14.
    Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16(3):432–6.PubMedGoogle Scholar
  15. 15.
    Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84(1):101–6.PubMedGoogle Scholar
  16. 16.
    Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol. 2014;133(1):98–103.e1–6.Google Scholar
  17. 17.
    Choi JH, Kim JH, Park HS. Upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2015;15(1):21–6.PubMedGoogle Scholar
  18. 18.
    Graefe H, Roebke C, Schafer D, Meyer JE. Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination. J Allergy (Cairo). 2012;2012:817910.Google Scholar
  19. 19.
    Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111(5):913–21; quiz 22.PubMedGoogle Scholar
  20. 20.
    Lee JY, Kim HM, Ye YM, Bahn JW, Suh CH, Nahm D, et al. Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma. Allergy Asthma Proc. 2006;27(5):341–6.PubMedGoogle Scholar
  21. 21.
    Kim SH, Sanak M, Park HS. Genetics of hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am. 2013;33(2):177–94.PubMedGoogle Scholar
  22. 22.
    Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, et al. HLA association in aspirin-intolerant asthma: DPB1∗0301 as a strong marker in a Korean population. J Allergy Clin Immunol. 2004;113(3):562–4.PubMedGoogle Scholar
  23. 23.
    Celik GE, Schroeder JT, Hamilton RG, Saini SS, Adkinson NF. Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2009;39(10):1522–31.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):163–76.PubMedGoogle Scholar
  25. 25.
    Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.Google Scholar
  26. 26.
    Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.PubMedGoogle Scholar
  27. 27.
    Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 2001;108(1):47–51.PubMedGoogle Scholar
  28. 28.
    Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46(8):2201–6.PubMedGoogle Scholar
  29. 29.
    Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005;42(2):127–31.PubMedGoogle Scholar
  30. 30.
    Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol. 2007;142(1):64–9.PubMedGoogle Scholar
  31. 31.
    Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma. 2004;41(1):67–75.PubMedGoogle Scholar
  32. 32.
    Comert S, Celebioglu E, Yucel T, Erdogan T, Karakaya G, Onerci M, et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68(11):1443–51.PubMedGoogle Scholar
  33. 33.
    Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81 e1.PubMedGoogle Scholar
  34. 34.
    White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):211–22.PubMedGoogle Scholar
  35. 35.
    Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118(4):801–4.PubMedGoogle Scholar
  36. 36.
    Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014;14(1):1–6.PubMedGoogle Scholar
  37. 37.
    Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90(3):338–41.PubMedGoogle Scholar
  38. 38.
    Burnett T, Katial R, Alam R. Mechanisms of aspirin desensitization. Immunol Allergy Clin North Am. 2013;33(2):223–36.PubMedGoogle Scholar
  39. 39.
    Aksu K, Kurt E, Alatas O, Gulbas Z. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2014;35(2):148–55.PubMedGoogle Scholar
  40. 40.
    Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133(1):286–7.e1–9.PubMedGoogle Scholar
  41. 41.
    Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172–4.PubMedGoogle Scholar
  42. 42.
    Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123(2):406–10.PubMedGoogle Scholar
  43. 43.
    Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105(2):130–5.PubMedGoogle Scholar
  44. 44.
    White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97(2):190–5.PubMedGoogle Scholar
  45. 45.
    Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120(2):273–7.PubMedGoogle Scholar
  46. 46.
    Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157–64.PubMedGoogle Scholar
  47. 47.
    Gosepath J, Schaefer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg. 2001;127(3):316–21.PubMedGoogle Scholar
  48. 48.
    Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–34.PubMedGoogle Scholar
  49. 49.
    Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–6.PubMedGoogle Scholar
  50. 50.
    Ibrahim C, Singh K, Tsai G, Huang D, Mazza J, Rotenberg B, et al. A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma. Allergy Asthma Clin Immunol. 2014;10(1):64.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Buchheit KM, Laidlaw TM. Update on the management of aspirin-exacerbated respiratory disease. Allergy Asthma Immunol Res. 2016;8(4):298–304.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Adile Berna Dursun
    • 1
  • Engin Dursun
    • 2
  • D. Donald Stevenson
    • 3
  1. 1.Division of Immunology and Allergic DiseasesSchool of Medicine, Recep Tayyip Erdogan UniversityRizeTurkey
  2. 2.Department of OtorhinolaryngologySchool of Medicine, Recep Tayyip Erdogan UniversityRizeTurkey
  3. 3.Division of Allergy, Asthma and ImmunologyScripps ClinicSan DiegoUSA

Personalised recommendations